Streetbeat News

Earnings

BRCC

BRC (NYSE:BRCC) reported a Q4 2023 GAAP EPS of $(0.070), improving from $(0.090) YoY. However, its sales of $119.650M missed the $123.752M estimate, despite being a 27.81% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 9:32 pm

ADT

GROV

PETS

RSI

VSCO

In Wednesday's after-market session, 11 consumer discretionary stocks showed significant movement. Notably, Rush Street Interactive (RSI) and Grove Collaborative Holdings (GROV) reported their Q4 earnings, leading to a 16.9% and 6.72% increase in their stock prices, respectively. Conversely, Victoria's Secret (VSCO) experienced a 19.1% decline after its Q4 earnings release. Other stocks such as PetMed Express (PETS) and ADT also saw notable price changes.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 9:31 pm

IOBT

NXL

RBOT

WORX

In Wednesday's after-market session, several healthcare stocks showed significant movement. SCWorx (WORX) led the gainers with a 60.8% increase, while Nexalin Technology (NXL) experienced the largest drop among the losers, falling 14.4%. Notable mentions include IO Biotech (IOBT) and Vicarious Surgical (RBOT), which released their Q4 earnings recently, influencing their stock movements.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 9:31 pm

HDSN

ROMA

STI

VATE

In Wednesday's after-market session, several industrials stocks saw significant movements. Roma Green Finance and Solidion Technology were among the top gainers, while Hudson Technologies and MingZhu Logistics Holdings led the losers. Notably, Hudson Technologies and Innovate released their Q4 earnings reports, influencing their stock prices.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 9:31 pm

CYN

INFN

OSPN

SASI

YEXT

In Wednesday's after-market session, several information technology stocks showed significant movement. Sigma Additive Solutions, OneSpan, and Yext were among the top gainers, with Sigma Additive Solutions leading at a 44.1% increase. On the losing end, Cyngn, MultiSensor AI Holdings, and Airship AI Holdings saw notable declines. The movements were largely influenced by the release of Q4 earnings reports for several companies.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 9:30 pm

KEQU

Kewaunee Scientific (NASDAQ:KEQU) reported a significant increase in Q3 EPS to $0.85, up from $0.25 YoY, despite a 23.09% decrease in sales to $46.78M from $60.82M YoY.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 9:30 pm

KLXE

KLX Energy Services Holdings (KLXE) reported Q4 2023 adjusted EPS of $(0.54), missing the $0.01 estimate, and sales of $194.20M, missing the $212.97M estimate. This represents a 13.03% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 9:30 pm

GILD

MRK

Gilead Sciences Inc (GILD) and Merck & Co Inc (MRK) announced successful Phase 2 clinical trial results for their HIV treatment combo of islatravir and lenacapavir, showing a 94.2% rate of viral suppression at 24 weeks. The study compared the efficacy of this combination against Gilead's Biktarvy, with both treatments showing comparable results. The trial will continue through Week 48, with future data presentations planned.

Portfolio Pulse from Vandana Singh

March 06, 2024 | 9:30 pm

KGS

Kodiak Gas Services has initiated its standalone 2024 Adjusted EBITDA guidance, projecting it to be between $460 million and $490 million.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 9:30 pm

CORZ

Core Scientific has entered into a long-term hosting contract with CoreWeave, providing up to 16 MW of data center infrastructure to support AI and HPC workloads, potentially generating over $100M in revenue. This strategic move leverages Core Scientific's expertise in high-value compute, expanding its revenue model to include customers in the rapidly growing HPC sector. The company has leased a data center in Austin, TX, previously occupied by Hewlett Packard, to facilitate this growth. The contract is expected to be accretive to Core Scientific's earnings in 2024.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 9:30 pm